CS
PTGX icon

Candriam SCA’s Protagonist Therapeutics PTGX Stock Holding History

Candriam SCA’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-162,492
Closed -$7.31M – 705
2024
Q3 		$7.31M Sell
162,492
-111,326
-41% -$4.5M 0.04% 304
2024
Q2 		$9.49M Sell
273,818
-86,182
-24% -$2.52M 0.06% 258
2024
Q1 		$10.4M Sell
360,000
-177,000
-33% -$4.82M 0.07% 250
2023
Q4 		$12.3M Sell
537,000
-93,000
-15% -$1.63M 0.09% 227
2023
Q3 		$10.5M Sell
630,000
-95,000
-13% -$1.84M 0.07% 226
2023
Q2 		$20M Buy
725,000
+100,000
+16% +$2.5M 0.14% 157
2023
Q1 		$13.2M Buy
+625,000
New +$10.5M 0.09% 219
2022
Q2 		– Sell
-83,646
Closed -$1.98M – 812
2022
Q1 		$1.98M Hold
83,646
– – 0.01% 544
2021
Q4 		$2.86M Hold
83,646
– – 0.02% 474
2021
Q3 		$1.48M Hold
83,646
– – 0.01% 630
2021
Q2 		$3.75M Buy
+83,646
New +$2.76M 0.03% 461

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Candriam SCA's PTGX Position: Q4 2024 in Review

Candriam SCA sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 162,492 shares — an estimated $7.31M sold.

Candriam SCA first reported a position in PTGX in Q2 2021 and held it in 11 quarters. The position peaked at $20M in Q2 2023. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Candriam SCA reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 162,492 Protagonist Therapeutics shares in Q4 2024, an estimated $7.31M.
  • Candriam SCA first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 11 quarters.
  • Candriam SCA's Protagonist Therapeutics position peaked at $20M in Q2 2023.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.